The startup operates a pharmaceutical company that enhances access to effective therapies through retail compounding programs and the identification of high-impact drug candidates. By enabling healthcare professionals to analyze scientific literature and provide insights on novel drug targets, the company addresses the challenge of limited availability of tailored medications.
Funding
$7.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many compounded medications with proven efficacy lack FDA approval, limiting their accessibility and standardization for widespread patient use. Existing delivery methods for these therapies may also be suboptimal, impacting patient compliance and treatment outcomes.
Solution
Steel Therapeutics seeks to bridge the gap between compounded medications and FDA-approved therapies by identifying high-impact drug candidates with a track record of efficacy in compounding pharmacies and optimizing their delivery methods. The company focuses on securing FDA approval for these therapies to increase patient access and improve safety. Their initial product, Fizurex™, is a single-use wipe containing a combination of nifedipine and lidocaine, a therapy commonly compounded for anal fissures. By converting this compounded treatment into a more convenient, standardized format and pursuing FDA approval, Steel Therapeutics aims to improve patient compliance and treatment outcomes.
Target Audience
The primary target audience includes patients seeking accessible and standardized treatment options and physicians looking for FDA-approved alternatives to compounded medications.
Features
- Focus on combination therapies with established efficacy in compounding pharmacies.
- Reformulation of compounded medications into user-friendly dosage forms.
- Lead product Fizurex™: a single-use, disposable wipe containing nifedipine and lidocaine for treating anal fissures.
- Pursuit of FDA approval to increase accessibility and ensure product safety.
- Streamlined regulatory and clinical development pathways for compounded therapies.